Drug Trial Radar · NCT07670897
Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jul 29, 2026
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, randomized, single-dose bioequivalence trial conducted in healthy adult participants.
Conditions
- T2D
Interventions
GZR4 injection ADrug
GZR4 s.c., single-dose
GZR4 injection BDrug
GZR4 s.c., single-dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Day1-Day29
- AUC₀-tTime frame: Day1-Day29
- AUC₀-∞Time frame: Day1-Day29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Shandong Co., Ltd.,
Linyi, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.